Actimed Therapeutics

Actimed Therapeutics

Therapeutics for cancer cachexia and muscle wasting disorders.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
N/A

€0.0

round
N/A

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

Valuation: €0.0

31.3x EV/Revenue

-5.4x EV/EBITDA

round
*

£1.0m

Valuation: £77.5m

97.2x EV/Revenue

-16.9x EV/EBITDA

Early VC
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
GBP20182019202120222023
Revenues00000000000000000000
% growth-51 %-(44 %)-
EBITDA00000000000000000000
% EBITDA margin(92 %)(153 %)(69 %)(576 %)-
Profit00000000000000000000
% profit margin(33 %)(144 %)(48 %)(448 %)(928 %)
EV00000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x
R&D budget00000000000000000000
R&D % of revenue-97 %---

Source: Company filings or news article

Notes (0)
More about Actimed Therapeutics
Made with AI
Edit

Actimed Therapeutics is a clinical-stage specialty pharmaceutical company, founded in 2017, focused on developing treatments for muscle wasting disorders, with a primary emphasis on cancer cachexia. The company was co-founded by Professors Andrew Coats and Stefan Anker, world-renowned physicians in cachexia and muscle wasting research, along with Yann Colardelle, a professional in medical education. Both academic founders have extensive experience, with Professor Coats having served as Dean of Medicine at the University of Sydney and head of Clinical Cardiology at Imperial College London, and Professor Anker having a long academic research career in heart failure and cachexia at institutions like the Royal Brompton Hospital and Charité Berlin.

The company's lead product is S-pindolol benzoate (ACM-001.1), a small molecule described as an Anabolic, Catabolic Transforming Agent (ACTA). It is being developed to treat cancer-related cachexia, a wasting disease that affects a high percentage of cancer patients and is responsible for a significant number of cancer deaths. S-pindolol has a multi-modal action, aiming to reduce weight loss (catabolism), increase muscle mass (anabolism), and improve appetite and fatigue. The company is preparing for Phase 2b/3 clinical trials (the IMPACT programme) for S-pindolol in patients with Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC). Additionally, Actimed is exploring the use of S-pindolol to preserve muscle mass in obese patients undergoing treatment with GLP-1 receptor agonists.

Actimed's second asset is S-oxprenolol, which is being developed for treating muscle wasting associated with amyotrophic lateral sclerosis (ALS). The company has licensed the global rights for S-oxprenolol's development in indications outside of ALS, including cancer cachexia, to the U.S.-based Faraday Pharmaceuticals, while retaining the rights for ALS. Based in London, UK, Actimed Therapeutics operates on a venture capital-backed business model, raising funds through financing rounds to advance its clinical pipeline. The company has successfully closed multiple seed and Series A funding rounds, with notable investment from Mankind Pharma.

Keywords: cancer cachexia, muscle wasting disorders, S-pindolol benzoate, ACM-001, S-oxprenolol, amyotrophic lateral sclerosis, clinical-stage biopharmaceutical, oncology, metabolic disorders, anabolic catabolic transforming agent, Non-Small Cell Lung Cancer, Colorectal Cancer, GLP-1, sarcopenic obesity, drug development, therapeutics, pharmacology, clinical trials, life sciences, specialty pharma

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads